Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
PanTracer™ LBx is now available! - Order now
The NEO | AML Express assay is a next-generation sequencing (NGS) assay using combined DNA- and RNA-sequencing, which is used to identify prognostically and diagnostically informative alterations in acute myeloid leukemia (AML). The DNA sequencing component of this assay detects single nucleotide variants (SNVs) and indels in genes recurrently mutated in AML, and the RNA sequencing component detects fusions involving genes that are frequently involved in structural rearrangements observed in AML, as noted below. Test reports include a summary interpretation of all results together.
DNA (38 genes): ABL1, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETV6, EZH2, FLT3 (ITD and TKD), GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PHF6, PPM1D, PRPF8, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
RNA (9 genes): ABL1, KAT6A, KMT2A, MECOM, MYH11, NUP214, NUP98, RARA, RUNX1
Bone Marrow Aspirate: 1-2 mL in EDTA tube.
Peripheral Blood: 2-3 mL in EDTA tube.
Note on fresh samples: NeoGenomics should receive within 7 days from collection for acceptable cell viability.
Client-Bill Only
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: July 28, 2025